RCSB PDB - 3QN7: Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA) (original) (raw)
Bicyclic peptide inhibitor reveals large contact interface with a protease target
[Angelini, A.](/search?q=citation.rcsb%5Fauthors:Angelini, A.), [Cendron, L.](/search?q=citation.rcsb%5Fauthors:Cendron, L.), [Chen, S.](/search?q=citation.rcsb%5Fauthors:Chen, S.), [Touati, J.](/search?q=citation.rcsb%5Fauthors:Touati, J.), [Winter, G.](/search?q=citation.rcsb%5Fauthors:Winter, G.), [Zanotti, G.](/search?q=citation.rcsb%5Fauthors:Zanotti, G.), [Heinis, C.](/search?q=citation.rcsb%5Fauthors:Heinis, C.)
(2012) ACS Chem Biol 7: 817-821
PubMed: 22304751 Search on PubMed
PubMed Abstract:
From a large combinatorial library of chemically constrained bicyclic peptides we isolated a selective and potent (K(i) = 53 nM) inhibitor of human urokinase-type plasminogen activator (uPA) and crystallized the complex. This revealed an extended structure of the peptide with both peptide loops engaging the target to form a large interaction surface of 701 Å(2) with multiple hydrogen bonds and complementary charge interactions, explaining the high affinity and specificity of the inhibitor. The interface resembles that between two proteins and suggests that these constrained peptides have the potential to act as small protein mimics.
Organizational Affiliation:
Institute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland.